Patents by Inventor Michael J. MASSARE

Michael J. MASSARE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20250025549
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: November 30, 2022
    Publication date: January 23, 2025
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
    Publication number: 20240423926
    Abstract: Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: September 9, 2024
    Publication date: December 26, 2024
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Gregory GLENN, Louis FRIES, III, Iksung CHO
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20240165221
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230330216
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 19, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20230293667
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.
    Type: Application
    Filed: August 10, 2022
    Publication date: September 21, 2023
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230070886
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 27, 2021
    Publication date: March 9, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY
    Publication number: 20220387579
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: May 23, 2022
    Publication date: December 8, 2022
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia OLIVER, Gregory GLENN
  • CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM
    Publication number: 20220354944
    Abstract: Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 10, 2022
    Inventors: Nita PATEL, Bin ZHOU, Mimi GUEBRE-XABIER, Jing-Hui TIAN, Alyse D. PORTNOFF, Michael J. MASSARE, Vivek SHINDE, Louis FRIES, Gale SMITH
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220332765
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 20, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220125914
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228708
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: February 8, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20210228709
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 29, 2021
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
    Publication number: 20210137845
    Abstract: Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: July 24, 2018
    Publication date: May 13, 2021
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Gregory GLENN, Louis FRIES, Iksung CHO
  • VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY
    Publication number: 20200101151
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: August 20, 2019
    Publication date: April 2, 2020
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia OLIVER, Gregory GLENN
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20200030436
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20190134187
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 9, 2019
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20190062713
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 28, 2019
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY
    Publication number: 20180133308
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: November 21, 2017
    Publication date: May 17, 2018
    Applicant: Novavax, Inc.
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia OLIVER, Gregory GLENN
  • VACCINE COMPOSITIONS CONTAINING MODIFIED ZIKA VIRUS ANTIGENS
    Publication number: 20170354729
    Abstract: The present disclosure relates to vaccine compositions that comprise a Zika virus antigen and an adjuvant. The present disclosure also provides methods for inducing a protective immune response by administering the disclosed vaccine compositions in a subject in needs thereof. The present methods also comprise the binding of the Zika virus vaccine to Zika virus cellular receptor proteins.
    Type: Application
    Filed: March 16, 2017
    Publication date: December 14, 2017
    Inventors: Ye LIU, Jing-Hui TIAN, Gale SMITH, Michael J. MASSARE, Sarathi BODDAPATI
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20170253861
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 7, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON